A share price of NewAmsterdam Pharma Company NV [NAMS] is currently trading at $37.0, down -2.50%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NAMS shares have gain 2.66% over the last week, with a monthly amount glided 20.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on August 25, 2025, and set its price target to $45. On July 17, 2025, Goldman initiated with a Neutral rating and assigned a price target of $27 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $42 on June 17, 2025. Stifel initiated its recommendation with a Buy and recommended $44 as its price target on June 10, 2025. Cantor Fitzgerald started tracking with an Overweight rating for this stock on June 04, 2025, and assigned it a price target of $42. In a note dated December 30, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $48 on this stock.
NewAmsterdam Pharma Company NV experienced fluctuations in its stock price throughout the past year between $14.06 and $41.47. Currently, Wall Street analysts expect the stock to reach $48.5 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $37.0 at the most recent close of the market. An investor can expect a potential return of 31.08% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
Trailing Twelve Months sales for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] were 64.01M which represents 740.06% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -2.59%, and Net Profit Margin reading is -2.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 36.20 points at the first support level, and at 35.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.89, and for the 2nd resistance point, it is at 38.79.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] is 21.08. As well, the Quick Ratio is 21.08, while the Cash Ratio is 15.44. Considering the valuation of this stock, the price to sales ratio is 65.10, the price to book ratio is 5.35.
Transactions by insiders
Recent insider trading involved Topper James N, Director, that happened on Sep 15 ’25 when 660.0 shares were purchased. Chief Accounting Officer, Kooij Louise Frederika completed a deal on Sep 09 ’25 to sell 0.15 million shares. Meanwhile, Director Topper James N bought 1260.0 shares on Sep 08 ’25.
